CD2+, CD3+, and CD19+ depletion after a course of antithymocyte globulin for a steroid-resistant rejection.
Grandtnerovà
B
B
Department of Internal Medicine, F.D. Roosevelt Hospital, Baskà Bystrica, Slovak Republic.
Mocikovà
H
H
Kohutovà
M
M
D000328:Adult; D015703:Antigens, CD / Q000032:analysis; D018941:Antigens, CD19 / Q000032:analysis*; D000961:Antilymphocyte Serum / Q000009:adverse effects / Q000627:therapeutic use*; D001402:B-Lymphocytes / Q000276:immunology; D001706:Biopsy; D018801:CD2 Antigens / Q000032:analysis*; D017252:CD3 Complex / Q000032:analysis*; D004351:Drug Resistance; D006084:Graft Rejection / Q000276:immunology* / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008212:Lymphocyte Depletion; D008775:Methylprednisolone / Q000627:therapeutic use; D013601:T-Lymphocytes / Q000276:immunology
D015703:Antigens, CD; D018941:Antigens, CD19; D000961:Antilymphocyte Serum; D018801:CD2 Antigens; D017252:CD3 Complex; D007166:Immunosuppressive Agents; D008775:Methylprednisolone